PubMed Entries
further Publications
Prof. Dr. Guus Rimmelzwaan
Aregay, A., Slunečko, J., Korva, M., Bogovic, P., Resman Rus, K., Knap, N., Beicht, J., Kubinski, M., Saletti, G., Avšič-Županc, T., Steffen, I., Strle, F., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins. Npj Vaccines, 9. https://doi.org/10.1038/s41541-024-00936-7
read more
read more
Agac, A., Kolbe, S. M., Ludlow, M., Osterhaus, A., Meineke, R., & Rimmelzwaan, G. F. (2023). Host responses to respiratory syncytial virus infection. Viruses, 15(10). https://doi.org/10.3390/v15101999
read more
read more
Beicht, J. (2023). Characterization of Langat virus- and vector-based vaccine approaches against tick-borne encephalitis virus. https://elib.tiho-hannover.de/receive/tiho_mods_00009397
read more
read more
Beicht, J., Kubinski, M., Zdora, I., Puff, C., Biermann, J., Gerlach, T., Baumgärtner, W., Sutter, G., Osterhaus, A., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1177324
read more
read more
Kubinski, M., Beicht, J., Zdora, I., Biermann, J., Puff, C., Gerlach, T., Tscherne, A., Baumgärtner, W., Osterhaus, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). A recombinant modified vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1182963
read more
read more
Kubinski, M., Beicht, J., Zdora, I., Saletti, G., Kircher, M., Petry-Gusmag, M., Steffen, I., Puff, C., Jung, K., Baumgärtner, W., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Prajeeth, C. K. (2023). Cross-reactive antibodies against Langat virus protect mice from lethal tick-borne encephalitis virus infection. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1134371
read more
read more
Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2023). FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants. IScience, 26(4). https://doi.org/10.1016/j.isci.2023.106309
read more
read more
Nair, N., Osterhaus, A., Rimmelzwaan, G., & Prajeeth, C. K. (2023). Rift Valley fever virus: infection, pathogenesis and host immune responses. Pathogens, 12(9). https://doi.org/10.3390/pathogens12091174
read more
read more
Oosting, S. F., van der Veldt, A. A. M., Fehrmann, R. S. N., Bhattacharya, A., van Binnendijk, R. S., GeurtsvanKessel, C. H., Dingemans, A.-M. C., Smit, E. F., Hiltermann, T. J. N., den Hartog, G., Jalving, M., Westphal, T. T., de Wilt, F., Ernst, S. M., Boerma, A., van Zijl, L., Rimmelzwaan, G. F., Kvistborg, P., van Els, C. A. C. M., … de Vries, E. G. E. (2023). Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors. ESMO Open: Cancer Horizons / European Society for Medical Oncology, 8(4). https://doi.org/10.1016/j.esmoop.2023.101599
read more
read more
Wilken, L., Stelz, S., Agac, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Recombinant modified vaccinia virus Ankara expressing a glycosylation mutant of dengue virus NS1 induces specific antibody and T-cell responses in mice. Vaccines, 11(4). https://doi.org/10.3390/vaccines11040714
read more
read more
Prajeeth K. Chittappen, PhD
Beicht, J., Kubinski, M., Zdora, I., Puff, C., Biermann, J., Gerlach, T., Baumgärtner, W., Sutter, G., Osterhaus, A., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1177324
read more
read more
Kubinski, M., Beicht, J., Zdora, I., Biermann, J., Puff, C., Gerlach, T., Tscherne, A., Baumgärtner, W., Osterhaus, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). A recombinant modified vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1182963
read more
read more
Kubinski, M., Beicht, J., Zdora, I., Saletti, G., Kircher, M., Petry-Gusmag, M., Steffen, I., Puff, C., Jung, K., Baumgärtner, W., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Prajeeth, C. K. (2023). Cross-reactive antibodies against Langat virus protect mice from lethal tick-borne encephalitis virus infection. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1134371
read more
read more
Nair, N., Osterhaus, A., Rimmelzwaan, G., & Prajeeth, C. K. (2023). Rift Valley fever virus: infection, pathogenesis and host immune responses. Pathogens, 12(9). https://doi.org/10.3390/pathogens12091174
read more
read more
Pilchová, V., Prajeeth, C. K., Jendrny, P., Twele, F., Meller, S., Pink, I., Fathi, A., Addo, M. M., Volk, H. A., Osterhaus, A., Köckritz-Blickwede, M. von, & Schulz, C. (2023). β-Propiolactone (BPL)-inactivation of SARS-Co-V-2: in vitro validation with focus on saliva from COVID-19 patients for scent dog training. Journal of Virological Methods, 317, 114733. https://doi.org/10.1016/j.jviromet.2023.114733
read more
read more
Wilken, L., Stelz, S., Agac, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Recombinant modified vaccinia virus Ankara expressing a glycosylation mutant of dengue virus NS1 induces specific antibody and T-cell responses in mice. Vaccines, 11(4). https://doi.org/10.3390/vaccines11040714
read more
read more
Wilken, L., Stelz, S., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Transient blockade of Type I Interferon signalling promotes replication of Dengue Virus strain D2Y98P in adult wild-type mice. Viruses, 15(4). https://doi.org/10.3390/v15040814
read more
read more
Michaely, L. M., Schuwerk, L., Allnoch, L., Schön, K., Waltl, I., Larsen, P.-K., Pavlou, A., Prajeeth, C. K., Rimmelzwaan, G. F., Becker, S. C., Kalinke, U., Baumgärtner, W., & Gerhauser, I. (2022). Intact type I interferon receptor signaling prevents hepatocellular necrosis but not encephalitis in a dose-dependent manner in Rift Valley fever virus infected mice. International Journal of Molecular Sciences, 23(20). https://doi.org/10.3390/ijms232012492
read more
read more
Petry, M., Palus, M., Leitzen, E., Mitterreiter, J. G., Huang, B., Kröger, A., Verjans, G. M. G. M., Baumgärtner, W., Rimmelzwaan, G. F., Růžek, D., Osterhaus, A., & Prajeeth, C. K. (2021). Immunity to TBEV related flaviviruses with reduced pathogenicity protects mice from disease but not from TBEV entry into the CNS. Vaccines, 9(3: 196). https://doi.org/10.3390/vaccines9030196
read more
read more
Kronenberg, J., Pars, K., Brieskorn, M., Prajeeth, C. K., Heckers, S., Schwenkenbecher, P., Skripuletz, T., Pul, R., Pavlou, A., & Stangel, M. (2019). Fumaric acids directly influence gene expression of neuroprotective factors in rodent microglia. International Journal of Molecular Sciences, 20(2: 325). https://doi.org/10.3390/ijms20020325
read more
read more
Husni Elhabesh, PhD
Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2023). FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants. IScience, 26(4). https://doi.org/10.1016/j.isci.2023.106309
read more
read more
Meineke, R. (2022). Inhibition of Host Kinase Activity: Effects on Influenza A Virus Infection and Host Cell Signaling. https://elib.tiho-hannover.de/receive/tiho_mods_00007171
read more
read more
Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2022). FDA-approved inhibitors of RTK/Raf signaling potently impair multiple steps of in vitro and ex vivo influenza A virus infections. Viruses, 14(9). https://doi.org/10.3390/v14092058
read more
read more
Becker, T., Elbahesh, H., Reperant, L. A., Rimmelzwaan, G. F., & Osterhaus, A. D. M. E. (2021). Influenza vaccines: successes and continuing challenges. The Journal of Infectious Diseases, 224(Supplement 4), 405-S419. https://doi.org/10.1093/infdis/jiab269
read more
read more
Palacios-Pedrero, M. Á., Osterhaus, A. D. M. E., Becker, T., Elbahesh, H., Rimmelzwaan, G. F., & Saletti, G. (2021). Aging and options to halt declining immunity to virus infections. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.681449
read more
read more
Ricke-Hoch, M., Stelling, E., Lasswitz, L., Gunesch, A. P., Kasten, M., Zapatero-Belinchón, F. J., Brogden, G., Gerold, G., Pietschmann, T., Montiel, V., Balligand, J.-L., Facciotti, F., Hirsch, E., Gausepohl, T., Elbahesh, H., Rimmelzwaan, G. F., Höfer, A., Kühnel, M. P., Jonigk, D., … Hilfiker-Kleiner, D. (2021). Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PLoS ONE, 16(8). https://doi.org/10.1371/journal.pone.0255335
read more
read more
Di, H., Elbahesh, H., & Brinton, M. A. (2020). Characteristics of human OAS1 isoform proteins. Viruses, 12(2: 152). https://doi.org/10.3390/v12020152
read more
read more
Meineke, R., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2020). Differential susceptibility of pandemic H1N1 and seasonal H3N2 Influenza A viruses to clinically-approved small molecule kinase inhibitors. In Stiftung Tierärztliche Hochschule Hannover (Ed.), 13th Graduate School Days: 20/21 November 2020 / Stiftung Tierärztliche Hochschule Hannover. Stiftung Tierärztliche Hochschule Hannover.
read more
read more
Saletti, G., Gerlach, T., Jansen, J. M., Molle, A., Elbahesh, H., Ludlow, M., Li, W., Bosch, B.-J., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2020). Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. Scientific Reports, 10: 21447. https://doi.org/10.1038/s41598-020-78506-9
read more
read more
Bergmann, S., & Elbahesh, H. (2019). Targeting the proviral host kinase, FAK, limits influenza a virus pathogenesis and NFkB-regulated pro-inflammatory responses. Virology, 534, 54–63. https://doi.org/10.1016/j.virol.2019.05.020
read more
read more